OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ:TBIO) today announced the launch of its MX-ICP CRC Analysis and MX-ICP Melanoma Analysis, two new liquid biopsy cancer panels based on the company’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology. These new tests are among the first to provide comprehensive coverage of all relevant genes for colorectal cancer (CRC) and melanoma and are intended to enable precision treatment decisions. They are available for clinical use through Transgenomic’s Oncology CLIA laboratory in Omaha, Nebraska.
